{"id":33404,"date":"2025-08-18T07:18:45","date_gmt":"2025-08-18T07:18:45","guid":{"rendered":"https:\/\/volity.io\/blog\/big-pharma-on-the-edge-patents-pitfalls-and-billions-at-stake-2\/"},"modified":"2026-05-19T18:51:12","modified_gmt":"2026-05-19T18:51:12","slug":"big-pharma-on-the-edge-patents-pitfalls-and-billions-at-stake","status":"publish","type":"post","link":"https:\/\/volity.io\/de\/cfd\/big-pharma-on-the-edge-patents-pitfalls-and-billions-at-stake\/","title":{"rendered":"Big Pharma am Abgrund: Patente, Fallen und Milliarden auf dem Spiel"},"content":{"rendered":"\n    <style>\n    .vd-wrap {\n        display: flex;\n        align-items: flex-start;\n        gap: 20px;\n        background: #ffffff;\n        border: 1px solid #f2f4f7;\n        border-left: 4px solid #c0392b;\n        border-radius: 12px;\n        padding: 24px;\n        margin: 30px 0;\n        box-sizing: border-box;\n        width: 100%;\n        box-shadow: 0 4px 20px rgba(0,0,0,0.04);\n        position: relative;\n        overflow: hidden;\n    }\n    .vd-wrap::after {\n        content: \"\";\n        position: absolute;\n        right: -20px;\n        bottom: -20px;\n        width: 100px;\n        height: 100px;\n        background: radial-gradient(circle, rgba(192, 57, 43, 0.03) 0%, transparent 70%);\n        pointer-events: none;\n    }\n    .vd-icon {\n        flex-shrink: 0;\n        background: #fff5f4;\n        border: 1px solid #fee2e1;\n        border-radius: 8px;\n        width: 40px;\n        height: 40px;\n        display: flex;\n        align-items: center;\n        justify-content: center;\n    }\n    .vd-icon svg { width: 22px; height: 22px; }\n    .vd-content { flex: 1; min-width: 0; }\n    .vd-label {\n        display: block;\n        font-size: 11px;\n        font-weight: 800;\n        letter-spacing: 0.1em;\n        text-transform: uppercase;\n        color: #c0392b;\n        margin-bottom: 8px;\n        font-family: \"Inter\", sans-serif;\n    }\n    .vd-text {\n        font-size: 14px;\n        line-height: 1.6;\n        color: #475467;\n        margin: 0;\n        font-family: \"Inter\", sans-serif;\n    }\n    .vd-text p { margin: 0 0 10px 0; }\n    .vd-text p:last-child { margin-bottom: 0; }\n    .vd-text strong { color: #101828; font-weight: 600; }\n    .vd-text a { color: #c0392b; text-decoration: underline; }\n    @media (max-width: 600px) {\n        .vd-wrap { flex-direction: column; gap: 12px; padding: 20px; }\n        .vd-icon { width: 32px; height: 32px; }\n    }\n    <\/style>\n\n    <div class=\"vd-wrap\" role=\"alert\" aria-label=\"Risikohinweis\">\n        <div class=\"vd-icon\">\n            <svg viewBox=\"0 0 24 24\" fill=\"none\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\">\n                <path d=\"M12 9V14M12 17.01L12.01 16.998M12 21C16.9706 21 21 16.9706 21 12C21 7.02944 16.9706 3 12 3C7.02944 3 3 7.02944 3 12C3 16.9706 7.02944 21 12 21Z\" stroke=\"#c0392b\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\"\/>\n            <\/svg>\n        <\/div>\n        <div class=\"vd-content\">\n            <span class=\"vd-label\">Regulatorischer Risikohinweis<\/span>\n            <div class=\"vd-text\"><p>Investitionen in Finanzprodukte sind mit Risiken verbunden. Verluste k\u00f6nnen den Wert Ihrer urspr\u00fcnglichen Investition \u00fcbersteigen.<\/p><\/div>\n        <\/div>\n    <\/div>\n\n<p>There&#8217;s a quiet ticking beneath the surface of the pharmaceutical industry &#8211; and it&#8217;s getting louder. Over half a trillion dollars in blockbuster drug sales are inching toward the patent cliff. As those protections fade, Big Pharma faces a reality check that could reshape everything from pricing power to pipelines.<\/p>\n\n<h2 class=\"wp-block-heading\" id=\"h-patents-are-expiring-and-fast\">Patents Are Expiring &#8211; and Fast<\/h2>\n\n<p>Medications like Keytruda (Merck), Eliquis (Pfizer), and Humira and Rinvoq (AbbVie) are all on the chopping block. Their patent protection is set to unravel between 2027 and 2036. These aren&#8217;t niche therapies; they&#8217;re revenue powerhouses. For AbbVie, just two of them made up nearly half of its income in 2024.<\/p>\n\n<p>When those patents expire, generic and biosimilar versions are poised to swoop in &#8211; and take massive bites out of Big Pharma&#8217;s margins.<\/p>\n\n<h2 class=\"wp-block-heading\" id=\"h-tangled-webs-of-patents-now-under-fire\">Tangled Webs of Patents &#8211; Now Under Fire<\/h2>\n\n<p>For years, drugmakers used &#8222;patent thickets&#8220; to keep competitors at bay. By filing dozens, even hundreds, of overlapping patents &#8211; sometimes after FDA approval &#8211; they built legal fortresses around single products.<\/p>\n\n<p>But a 2024 JAMA study exposed that 75% of those patents had little to do with active ingredients &#8211; they were just legal padding. And now, Washington is cracking down. In 2025, lawmakers pushed forward bills aimed at capping how many patents can be weaponised in court. If passed, it could drastically shorten how long drugmakers can keep rivals out.<\/p>\n\n<h2 class=\"wp-block-heading\" id=\"h-cash-rich-but-nowhere-to-spend\">Cash-Rich&#8230; but Nowhere to Spend?<\/h2><p>For sector-specific stock investing context, see <a href=\"https:\/\/volity.io\/de\/aktien\/stock-market-sectors\/\">Marktsektoren: Rotations-Trends 2026<\/a>, <a href=\"https:\/\/volity.io\/de\/aktien\/blue-chip-aktien\/\">Blue-Chip-Aktien: Sind sie gut f\u00fcr Investitionen?<\/a>, and <a href=\"https:\/\/volity.io\/de\/aktien\/fundamentalanalyse\/\">Fundamentalanalyse: Bewertung des Aktienwerts<\/a>.<\/p>\n\n<p>Pharma&#8217;s pockets are deep &#8211; really deep. With over $700 billion in M&amp;A capacity ready to go, you&#8217;d think the next wave of biotech deals would be booming. Except&#8230; there&#8217;s a catch.<\/p>\n\n<p>The ideal acquisition targets &#8211; biotechs with real revenue and not just &#8222;science experiments&#8220; &#8211; are rare. And when deals do happen, they don&#8217;t always pan out. Since 2018, around 80% of biotech IPOs have flopped, wiping out billions in investor capital and leaving M&amp;A teams spooked.<\/p>\n\n<h2 class=\"wp-block-heading\" id=\"h-a-policy-storm-is-brewing\">A Policy Storm Is Brewing<\/h2>\n\n<p>It&#8217;s not just patents. A new proposal could slap a 1-5% IP tax on biotech patents &#8211; a sharp departure from the current flat structure. This change would affect how companies (and investors) value intellectual property, and how aggressively they pursue R&amp;D.<\/p>\n\n<p>Even elite academic institutions are under scrutiny. Harvard, sitting on 58,000+ patents and hundreds of licensing deals, is now facing a federal probe for alleged lapses in federally funded research disclosures. If the investigation leads to sanctions, the entire model of university-to-industry innovation may be shaken.<\/p>\n\n<h2 class=\"wp-block-heading\" id=\"h-so-what-happens-next\">So, What Happens Next?<\/h2>\n\n<p>To survive this shift, Big Pharma has to juggle three tough demands:<\/p>\n\n<ul class=\"wp-block-list\">\n<li>Keep innovation alive &#8211; through internal R&amp;D and external deals;<\/li>\n\n\n\n<li>Defend their patent arsenals &#8211; without triggering legal or political backlash;<\/li>\n\n\n\n<li>Deploy capital wisely &#8211; in a market that no longer rewards hype.<\/li>\n<\/ul>\n\n<p>Valuations may look cheap, but investors beware: some of these stocks are sitting on quicksand. The patent cliff isn&#8217;t just a calendar event &#8211; it&#8217;s a map of who&#8217;s exposed, who&#8217;s scrambling for new growth, and who&#8217;s quietly building resilience.<\/p>\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n<h2 class=\"wp-block-heading\" id=\"h-algorithms-vs-patients-how-ai-in-insurance-is-rewriting-healthcare\">Algorithms vs Patients: How AI in Insurance Is Rewriting Healthcare<\/h2>\n\n<p>AI was supposed to transform healthcare-and in some ways, it has. But revolutions aren&#8217;t always tidy. Quietly, insurers have rolled out artificial intelligence not to heal, but to trim costs. Increasingly, that translates into a single word for patients: &#8222;no.&#8220;<\/p>\n\n<h2 class=\"wp-block-heading\" id=\"h-denials-at-machine-speed\">Denials at Machine Speed<\/h2>\n\n<p>Here&#8217;s the crux: many insurers now run prior authorizations &#8211; the &#8222;will we cover this?&#8220; gate &#8211; through AI systems. And the twist is brutal: these tools aren&#8217;t recommending care; they&#8217;re rejecting it.<\/p>\n\n<p>In one prominent case, an insurer&#8217;s PXDX system plowed through more than 300,000 claims in two months. Human doctors &#8222;reviewed&#8220; files at a pace of 1.2 seconds each. That isn&#8217;t clinical judgment; that&#8217;s automation with a strobe light.<\/p>\n\n<p>Try appealing? Odds are bleak. Fewer than 0.2% of denials in ACA marketplace plans are appealed, and an even smaller share prevail.<\/p>\n\n<h2 class=\"wp-block-heading\" id=\"h-black-boxes-thin-oversight\">Black Boxes, Thin Oversight<\/h2>\n\n<p>These algorithms aren&#8217;t regulated like drugs or medical devices. They&#8217;re proprietary and opaque. The FDA doesn&#8217;t touch them. There&#8217;s no mandated transparency, no common fairness standard, no assurance that bias has been rooted out.<\/p>\n\n<p>And the harm is not hypothetical. Physicians report patients abandoning care after denials. An estimated 94% say prior authorization delays needed treatment; one in four have witnessed serious harm tied to those delays.<\/p>\n\n<h2 class=\"wp-block-heading\" id=\"h-the-slow-pushback\">The Slow Pushback<\/h2>\n\n<p>Yes, there&#8217;s noise. More than 50 insurers have pledged to streamline prior auth &#8211; fewer hoops, clearer rules. Industry has made promises before.<\/p>\n\n<p>Meanwhile, the No Surprises Act reshaped the battlefield. Providers filed roughly 1.5 million disputes in 2024, far beyond forecasts. The administrative toll of that fight? North of $300 million.<\/p>\n\n<h2 class=\"wp-block-heading\" id=\"h-when-algorithms-get-overruled\">When Algorithms Get Overruled<\/h2>\n\n<p>Here&#8217;s the kicker: when these AI-driven denials are challenged by lawyers &#8211; not patients &#8211; they often crumble. A major insurer&#8217;s model, nHPredict, saw about 90% of its decisions overturned by federal judges. That signals more than error; it signals a broken process.<\/p>\n\n<p>Appeals take time, though. Months, sometimes years. Too many patients don&#8217;t have that runway. Some never live to see a reversal.<\/p>\n\n<h2 class=\"wp-block-heading\" id=\"h-can-ai-be-trusted-with-care-decisions\">Can AI Be Trusted With Care Decisions?<\/h2>\n\n<p>AI can streamline paperwork and flag errors. But when algorithms dictate care without real human oversight, it gets dangerous. Accountability is missing. Regulation lags. And patients are trapped in a system optimized less for health than for savings.<\/p>\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n<h2 class=\"wp-block-heading\" id=\"h-who-pays-for-science-the-political-fight-for-america-s-research-future\">Who Pays for Science? The Political Fight for America&#8217;s Research Future<\/h2>\n\n<p>Science isn&#8217;t supposed to be campaign fodder, yet here we are. In 2025, the institutions behind gene editing, pandemic vaccines, and decades of biomedical wins are being pulled into budget brawls and ideological trench wars.<\/p>\n\n<h2 class=\"wp-block-heading\" id=\"h-public-science-on-the-chopping-block\">Public Science on the Chopping Block<\/h2>\n\n<p>NIH. CDC. NSF. BARDA. Once the crown jewels of U.S. research. This year, each took a hit &#8211; some, a heavy one. BARDA alone canceled 22 public-private projects in 2025, the same agency that helped rocket mRNA vaccines from lab bench to clinic.<\/p>\n\n<p>At the FDA, leadership churn looks like a revolving door. And the CDC&#8217;s vaccine advisory committee? Swept aside in one stroke by RFK Jr. It&#8217;s not only about dollars anymore; it&#8217;s about who holds the steering wheel.<\/p>\n\n<h2 class=\"wp-block-heading\" id=\"h-what-happens-when-you-defund-discovery\">What Happens When You Defund Discovery?<\/h2>\n\n<p>Cracks show quickly. Measles outbreaks are the worst in more than thirty years. Vaccine hesitancy is back on front pages. Biotech pipelines slow &#8211; not for lack of ideas, but for lack of grants to push them forward.<\/p>\n\n<p>Even the academic heavyweights aren&#8217;t insulated. Harvard &#8211; yes, that Harvard &#8211; is under federal investigation over how federally funded research translates into patents. If regulators come down hard, the university-to-industry bridge could wobble, maybe break.<\/p>\n\n<h2 class=\"wp-block-heading\" id=\"h-the-private-sector-can-t-do-it-alone\">The Private Sector Can&#8217;t Do It Alone<\/h2>\n\n<p>Here&#8217;s the uncomfortable bit: private capital rarely bankrolls the earliest, murkiest stages of discovery. It waits until risk is sanded down. mRNA? That took decades of public support before venture money arrived.<\/p>\n\n<p>Cut that base layer now, and you don&#8217;t just slow science &#8211; you erase futures that never get the chance to exist.<\/p>\n\n<h2 class=\"wp-block-heading\" id=\"h-why-are-we-doing-this\">Why Are We Doing This?<\/h2>\n\n<p>Politics, mostly. Science has no voting bloc, no quick wins. It&#8217;s slow, technical, occasionally maddening &#8211; and expensive. When the budget knives come out, research is often first on the cutting board.<\/p>\n\n<h2 class=\"wp-block-heading\" id=\"h-what-s-at-stake-is-resilience\">What&#8217;s at Stake Is Resilience<\/h2>\n\n<p>The capacity to meet the next virus, the next antibiotic failure, the next unknown. Hollow out the ecosystem and we&#8217;ll be flying with instruments off.<\/p>\n\n<h2 class=\"wp-block-heading\" id=\"h-a-call-for-recommitment\">A Call for Recommitment<\/h2>\n\n<p>If the U.S. wants to lead in life sciences, it needs more than brilliant labs &#8211; it needs political will. Ring-fence research budgets from election cycles. Treat the NIH and its peers as strategic assets, not chew toys.<\/p>\n\n<p>Investors, health leaders, voters alike have skin in this game. Funding isn&#8217;t only a line item; it&#8217;s a statement of values about the future we will have.<\/p>\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n<h2 class=\"wp-block-heading\" id=\"h-why-you-re-getting-sicker-the-quiet-collapse-of-american-healthcare-access\">Why You&#8217;re Getting Sicker: The Quiet Collapse of American Healthcare Access<\/h2>\n\n<p>It isn&#8217;t a new virus, and it isn&#8217;t a tech shortfall. It&#8217;s something duller, more structural. Health outcomes in the U.S. are sliding, and the culprit isn&#8217;t medicine so much as the on-ramp to it. In 2025, that on-ramp is cracking.<\/p>\n\n<h2 class=\"wp-block-heading\" id=\"h-shrinking-coverage-rising-costs\">Shrinking Coverage, Rising Costs<\/h2>\n\n<p>Start with the basics. Medicaid enrolment has rolled backward &#8211; more than 10 million people dropped after pandemic protections ended, many for paperwork glitches that should be fixable with a phone call&#8230; except the call center is jammed and the deadline passed.<\/p>\n\n<p>Meanwhile, employer plans cost more and cover less. Deductibles creep up. Out-of-pocket maxes bite. Being &#8222;insured&#8220; often means paying a premium for the privilege of still being exposed.<\/p>\n\n<h2 class=\"wp-block-heading\" id=\"h-it-s-not-just-you-it-s-the-system\">It&#8217;s Not Just You &#8211; It&#8217;s the System<\/h2>\n\n<p>Across the map, people are using less care &#8211; not because they&#8217;re suddenly healthier, but because they&#8217;re bill-shy. Screenings slip. Preventive visits get punted. Conditions smolder until they become five-alarm fires.<\/p>\n\n<p>And yet the industry&#8217;s profit engine hums: healthcare EBITDA is projected to swell by $300B+ by 2028. The system earns more even as patients receive less.<\/p>\n\n<h2 class=\"wp-block-heading\" id=\"h-the-ai-denial-machine\">The AI Denial Machine<\/h2>\n\n<p>To rub salt in it, AI is now a quiet gatekeeper. Insurers deploy automated prior-auth and claims tools that swat down approvals at scale. Some life-saving therapies get flagged &#8222;no&#8220; by default. Appeals exist on paper; in reality, they&#8217;re rare, slow, and punishing.<\/p>\n\n<p>Efficient? Extremely. Profitable? Yes. But it pushes people off the care path.<\/p>\n\n<h2 class=\"wp-block-heading\" id=\"h-winners-and-losers\">Winners and Losers<\/h2>\n\n<p>The split widens. Wealthier patients still find concierge slots, experimental meds, even offshore surgeries if needed. Everyone else navigates shrinking networks, surprise bills, and long delays.<\/p>\n\n<p>This isn&#8217;t merely an affordability hiccup; it&#8217;s structural failure &#8211; the richest healthcare system on Earth struggling to deliver basic access to millions.<\/p>\n\n<h2 class=\"wp-block-heading\" id=\"h-the-real-cost\">The Real Cost<\/h2>\n\n<p>When access erodes, the downstream flood follows. Chronic disease goes unmanaged. Mental health worsens. Life expectancy falls &#8211; three years in a row in the U.S., recently. Productivity sags, innovation slows, inequality digs in.<\/p>\n\n<p>So yes, Americans are getting sicker. And no, that&#8217;s not bad luck &#8211; it&#8217;s policy, process, and design.<\/p>\n\n<h2 class=\"wp-block-heading\" id=\"h-5-trading-and-investment-ideas\"><strong>5 trading and investment ideas<\/strong><\/h2>\n\n<p>Here are <strong>5 trading and investment ideas<\/strong> directly inspired by insights from the article &#8211; spanning pharma, biotech, healthcare policy risk, and long-term innovation exposure:<\/p>\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n<h3 class=\"wp-block-heading\">\ud83d\udca1 <strong>1. Long: Oversold Large-Cap Pharma (Deep Value Play)<\/strong><\/h3>\n\n<p><strong>Examples:<\/strong> Merck (MRK), Bristol Myers Squibb (BMY), AbbVie (ABBV)<br\/><strong>Why:<\/strong> Trading at 8-10\u00d7 forward earnings &#8211; near historic crisis valuations &#8211; despite strong pipelines and dividend support. The patent cliff is real, but largely priced in. Watch for rebound as investor focus rotates back to fundamentals.<\/p>\n\n<p><strong>Catalyst:<\/strong> Legislative compromise on IP reforms; surprise M&amp;A deals; pipeline readouts.<\/p>\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n<h3 class=\"wp-block-heading\">\ud83d\udca1 <strong>2. Short: AI-Dependent Health Insurers (Policy Risk Play)<\/strong><\/h3>\n\n<p><strong>Examples:<\/strong> UnitedHealth (UNH), Cigna (CI), Elevance Health (ELV)<br\/><strong>Why:<\/strong> AI-powered prior-authorisation tools face regulatory scrutiny and potential lawsuits. Denial-based profit models may be unsustainable. Legal pushback and patient backlash could compress margins.<\/p>\n\n<p><strong>Catalyst:<\/strong> Federal intervention, class-action lawsuits, No Surprises Act enforcement expansion.<\/p>\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n<h3 class=\"wp-block-heading\">\ud83d\udca1 <strong>3. Long: Science Infrastructure ETFs &amp; Contract Research Orgs<\/strong><\/h3>\n\n<p><strong>Examples:<\/strong> IBB, XBI (biotech ETFs); Thermo Fisher (TMO), Charles River Labs (CRL)<br\/><strong>Why:<\/strong> Public science cuts create white space for private R&amp;D enablers. If NIH\/NFS budgets shrink, CROs and toolmakers may gain from outsourced innovation.<\/p>\n\n<p><strong>Catalyst:<\/strong> Shifts in federal budget allocations; rising private sector research funding.<\/p>\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n<h3 class=\"wp-block-heading\">\ud83d\udca1 <strong>4. Event-Driven Play: Biotech M&amp;A Targets<\/strong><\/h3>\n\n<p><strong>Criteria:<\/strong> Revenue-generating, derisked Phase III biotechs; undervalued after IPO crashes<br\/><strong>Screeners:<\/strong> Look for sub-$5B names with cash on hand and late-stage oncology, immunology, or CNS pipelines.<\/p>\n\n<p><strong>Why:<\/strong> Big Pharma is sitting on &gt;$700B in firepower but struggling to find digestible targets. When the logjam breaks, takeovers will be fast and rich.<\/p>\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n<h3 class=\"wp-block-heading\">\ud83d\udca1 <strong>5. Long-Term Thematic: Global Health Access + Digital Health<\/strong><\/h3>\n\n<p><strong>Examples:<\/strong> Teladoc (TDOC), Doximity (DOCS), Philips (PHG); emerging market hospital chains<br\/><strong>Why:<\/strong> Structural decline in US access creates a tailwind for alternative models. Global demand for affordable, digital-first care is rising. Countries outside the US may leapfrog broken models.<\/p>\n\n<p><strong>Catalyst:<\/strong> International health investment, AI-healthcare platforms, developing-market adoption.<\/p>\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n<h2 class=\"wp-block-heading\">Volity: Where Any Volume Finds Agility<\/h2>\n\n<p>At Volity, we believe health and finance are connected. When people can&#8217;t access care, they can&#8217;t engage in opportunity. That&#8217;s why we support transparent markets and informed decision-making.<br\/><strong>Find your edge at <a href=\"https:\/\/volity.io\/\">volity.io<\/a>.<\/strong><\/p>\n<div class=\"quick-answer\" data-volity-unique=\"1\" style=\"background:#f7f7f7;border-left:4px solid #0066cc;padding:12px 16px;margin:16px 0;\"><strong>Quick answer:<\/strong> Big Pharma sits in the middle of a structural patent-cliff cycle through 2027-2030 that will see roughly $200 billion of branded-drug revenue exposed to biosimilar and generic competition, with Inflation Reduction Act Medicare price-negotiation rounds adding a second wave of margin pressure on the U.S. franchise. The 2026 picture is dominated by the GLP-1 obesity-and-diabetes franchise (Eli Lilly and Novo Nordisk), Keytruda exclusivity expiry on the horizon for Merck, and the post-Humira biosimilar landscape redefining how branded-biologic launches are priced. The trade is no longer &#8222;pharma is defensive&#8220;; the trade is now stock-by-stock pipeline replenishment versus revenue-cliff exposure.<\/p>\n<p style=\"margin:8px 0 0;\"><em>By Alexander Bennett, Volity research desk.<\/em><\/p>\n<\/div>\n<p><strong>What our analysts watch:<\/strong> Three reads anchor a serious pharma equity view that filters the louder narrative. Pipeline-replenishment ratio, measured as the present value of Phase III and registrational-stage assets against the present value of revenue exposed to patent expiry inside the next 60 months, separates structurally protected franchises from late-cycle melt risk. FDA Center for Drug Evaluation and Research approval cadence against the historical mean signals where regulatory throughput is supportive or restrictive of new-launch momentum. And Medicare IRA negotiation exposure (the published list of CMS-negotiated drugs and the cohort scheduled for the next negotiation rounds) tells which U.S. franchises will see administered-price compression and on what timeline. The combination filters most of the noise that quarterly EPS commentary adds.<\/p>\n<hr>\n<h2 id=\"faq\" data-volity-unique=\"1\">Frequently asked questions<\/h2>\n<h3>How big is the 2026-2030 patent cliff actually, in dollar terms?<\/h3>\n<p>Industry consensus places branded-drug revenue exposed to loss-of-exclusivity at roughly $200 billion across the 2026-2030 window, with biologics representing a materially larger share than in prior cliff cycles. The <a href=\"https:\/\/www.fda.gov\/drugs\/development-approval-process-drugs\/drug-approvals-and-databases\" rel=\"nofollow noopener\" target=\"_blank\">FDA drug approvals and databases hub<\/a> publishes the Orange Book and Purple Book reference lists that institutional desks reconcile against company-disclosed exclusivity calendars. The structural read for allocators: cliff exposure is highly concentrated in a handful of mega-franchises, and the dispersion across the major pharma names is wider than the headline aggregate suggests.<\/p>\n<h3>How does the FDA approval cadence compare to historical norms in 2026?<\/h3>\n<p>The FDA Center for Drug Evaluation and Research approved a record cohort of novel drugs in 2024-2025, with cell and gene therapies and oncology leading the count. <a href=\"https:\/\/www.investopedia.com\/\" rel=\"nofollow noopener\" target=\"_blank\">Investopedia coverage of pharma sector dynamics<\/a> covers the sector framework with current market context, although its company list is dated. The 2026 read: regulatory throughput is supportive of new-launch momentum, but Medicare price negotiation has compressed the launch-economics distribution by a meaningful margin in U.S.-pricing-sensitive franchises.<\/p>\n<h3>How should retail traders size pharma CFD exposure under EU rules?<\/h3>\n<p>Under the <a href=\"https:\/\/www.esma.europa.eu\/policy-rules\/mifid-ii-and-mifir\/investor-protection-and-intermediaries\/product-intervention\" rel=\"nofollow noopener\" target=\"_blank\">ESMA product intervention framework for retail CFDs<\/a>, EU retail leverage on individual equities is capped at 5:1, with mandatory negative-balance protection and standardised risk warnings. Pharma names carry asymmetric event risk (FDA decisions, trial data drops, Medicare negotiation announcements) that materially widens stop-loss requirements relative to broad-index exposure. Volity, accessed via UBK Markets under CySEC licence 186\/12, lists liquid pharma single-stock CFDs with segregated client funds and standardised retail disclosure.<\/p>\n<hr>\n<h2 class=\"wp-block-heading\" id=\"related-guides\">Related guides<\/h2>\n<ul>\n<li><a href=\"https:\/\/volity.io\/de\/aktien\/stocks-investing-for-beginners\/\">Aktien-Investment 101: So bauen Sie jetzt Verm\u00f6gen auf<\/a><\/li>\n<li><a href=\"https:\/\/volity.io\/de\/aktien\/best-stock-trading-platforms-in-europe-2026\/\">Beste europ\u00e4ische Broker 2026: Vollst\u00e4ndiger Vergleich<\/a><\/li>\n<li><a href=\"https:\/\/volity.io\/de\/aktien\/best-ai-stocks-for-investment\/\">Top KI-Aktien zum Kauf 2026<\/a><\/li>\n<li><a href=\"https:\/\/volity.io\/de\/trading-platforms-de\/best-trading-platforms\/\">Top-Trading-Plattformen 2026: beste Broker f\u00fcr Forex, Aktien und Krypto<\/a><\/li>\n<li><a href=\"https:\/\/volity.io\/forex\/risk-management\/\">Smarteres Risikomanagement im Forex-Trading<\/a><\/li>\n<\/ul>\n\n    <style>\n    .volity-coi {\n        background: #fff;\n        border: 1px solid #c5d8ee;\n        border-radius: 8px;\n        margin: 32px 0;\n        font-family: \"Inter\", sans-serif;\n        font-size: 13.5px;\n        line-height: 1.75;\n        color: #4a4a4a;\n        box-sizing: border-box;\n        width: 100%;\n        overflow: hidden;\n    }\n    .volity-coi .coi-heading {\n        display: block;\n        background: #2c6fad;\n        color: #fff;\n        font-size: 11px;\n        font-weight: 700;\n        letter-spacing: 0.09em;\n        text-transform: uppercase;\n        padding: 9px 22px;\n        margin: 0;\n    }\n    .volity-coi .coi-body { padding: 16px 22px; }\n    .volity-coi .coi-body p { margin: 0 0 10px 0; }\n    .volity-coi .coi-body p:last-child { margin-bottom: 0; }\n    .volity-coi a { color: #2c6fad; text-decoration: underline; }\n    @media(max-width:480px) {\n        .volity-coi .coi-body { padding: 14px 16px; font-size: 13px; }\n        .volity-coi .coi-heading { padding: 8px 16px; }\n    }\n    <\/style>\n    <div class=\"volity-coi\" role=\"note\">\n        <span class=\"coi-heading\">\u24d8 Hinweis<\/span>\n        <div class=\"coi-body\"><p>Volity betreibt eine Handelsplattform und ver\u00f6ffentlicht au\u00dferdem Bildungs- und Analyseinhalte zum Thema Trading. Die Inhalte dieser Seite dienen ausschlie\u00dflich Bildungszwecken und sind nicht als Finanzberatung zu verstehen. Volity kann kommerziell profitieren, wenn Leser \u00fcber Links auf dieser Website Handelskonten er\u00f6ffnen.<\/p><p>Unsere Inhalte werden nach dokumentierten <a href=\"https:\/\/volity.io\/de\/editorial-standards\/\">redaktionellen Standards<\/a> erstellt und gepr\u00fcft; die Vergleichs- und Bewertungsmethodik wird <a href=\"https:\/\/volity.io\/de\/editorial-standards\/review-methodology\/\">hier<\/a> ver\u00f6ffentlicht.<\/p><\/div>\n    <\/div>\n","protected":false},"excerpt":{"rendered":"<p>There&#8217;s a quiet ticking beneath the surface of the pharmaceutical industry &#8211; and it&#8217;s getting louder. Over half a trillion dollars in [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":17935,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"custom_schema":"","footnotes":""},"categories":[195],"tags":[],"class_list":["post-33404","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-cfd"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.6) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Big Pharma am Abgrund - Volity<\/title>\n<meta name=\"description\" content=\"Wie KI-Ablehnungen, auslaufende Patente, schrumpfender Versicherungsschutz und politische Angriffe das US-Gesundheitswesen umformen.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/volity.io\/de\/cfd\/big-pharma-on-the-edge-patents-pitfalls-and-billions-at-stake\/\" \/>\n<meta property=\"og:locale\" content=\"de_DE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Big Pharma am Abgrund: Patente, Fallen und Milliarden auf dem Spiel\" \/>\n<meta property=\"og:description\" content=\"Wie KI-Ablehnungen, auslaufende Patente, schrumpfender Versicherungsschutz und politische Angriffe das US-Gesundheitswesen umformen.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/volity.io\/de\/cfd\/big-pharma-on-the-edge-patents-pitfalls-and-billions-at-stake\/\" \/>\n<meta property=\"og:site_name\" content=\"Volity\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61570055360264\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-18T07:18:45+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-05-19T18:51:12+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/volity.io\/wp-content\/uploads\/2025\/08\/Rod-of-Asclepius.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1456\" \/>\n\t<meta property=\"og:image:height\" content=\"816\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"Alexander Bennett\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@VolityBeat\" \/>\n<meta name=\"twitter:site\" content=\"@VolityBeat\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Alexander Bennett\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"13\u00a0Minuten\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/volity.io\\\/de\\\/cfd\\\/big-pharma-on-the-edge-patents-pitfalls-and-billions-at-stake\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/volity.io\\\/de\\\/cfd\\\/big-pharma-on-the-edge-patents-pitfalls-and-billions-at-stake\\\/\"},\"author\":{\"name\":\"Alexander Bennett\",\"@id\":\"https:\\\/\\\/volity.io\\\/de\\\/#\\\/schema\\\/person\\\/b331ae22e808d4e5c67047ab75976841\"},\"headline\":\"Big Pharma am Abgrund: Patente, Fallen und Milliarden auf dem Spiel\",\"datePublished\":\"2025-08-18T07:18:45+00:00\",\"dateModified\":\"2026-05-19T18:51:12+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/volity.io\\\/de\\\/cfd\\\/big-pharma-on-the-edge-patents-pitfalls-and-billions-at-stake\\\/\"},\"wordCount\":2606,\"publisher\":{\"@id\":\"https:\\\/\\\/volity.io\\\/de\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/volity.io\\\/de\\\/cfd\\\/big-pharma-on-the-edge-patents-pitfalls-and-billions-at-stake\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/volity.io\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/Rod-of-Asclepius.webp\",\"articleSection\":[\"CFD\"],\"inLanguage\":\"de\",\"speakable\":{\"@type\":\"SpeakableSpecification\",\"cssSelector\":[\"h1\",\".entry-content > p:first-of-type\",\".entry-content h2\",\".faq-question\",\"[data-volity-takeaways]\"]}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/volity.io\\\/de\\\/cfd\\\/big-pharma-on-the-edge-patents-pitfalls-and-billions-at-stake\\\/\",\"url\":\"https:\\\/\\\/volity.io\\\/de\\\/cfd\\\/big-pharma-on-the-edge-patents-pitfalls-and-billions-at-stake\\\/\",\"name\":\"Big Pharma am Abgrund - Volity\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/volity.io\\\/de\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/volity.io\\\/de\\\/cfd\\\/big-pharma-on-the-edge-patents-pitfalls-and-billions-at-stake\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/volity.io\\\/de\\\/cfd\\\/big-pharma-on-the-edge-patents-pitfalls-and-billions-at-stake\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/volity.io\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/Rod-of-Asclepius.webp\",\"datePublished\":\"2025-08-18T07:18:45+00:00\",\"dateModified\":\"2026-05-19T18:51:12+00:00\",\"description\":\"Wie KI-Ablehnungen, auslaufende Patente, schrumpfender Versicherungsschutz und politische Angriffe das US-Gesundheitswesen umformen.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/volity.io\\\/de\\\/cfd\\\/big-pharma-on-the-edge-patents-pitfalls-and-billions-at-stake\\\/#breadcrumb\"},\"inLanguage\":\"de\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/volity.io\\\/de\\\/cfd\\\/big-pharma-on-the-edge-patents-pitfalls-and-billions-at-stake\\\/\"]}],\"speakable\":{\"@type\":\"SpeakableSpecification\",\"cssSelector\":[\"h1\",\".entry-content > p:first-of-type\",\".entry-content h2\",\".faq-question\",\"[data-volity-takeaways]\"]}},{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/volity.io\\\/de\\\/cfd\\\/big-pharma-on-the-edge-patents-pitfalls-and-billions-at-stake\\\/#primaryimage\",\"url\":\"https:\\\/\\\/volity.io\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/Rod-of-Asclepius.webp\",\"contentUrl\":\"https:\\\/\\\/volity.io\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/Rod-of-Asclepius.webp\",\"width\":1456,\"height\":816,\"caption\":\"Rod of Asclepius\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/volity.io\\\/de\\\/cfd\\\/big-pharma-on-the-edge-patents-pitfalls-and-billions-at-stake\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/volity.io\\\/de\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Big Pharma am Abgrund: Patente, Fallen und Milliarden auf dem Spiel\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/volity.io\\\/de\\\/#website\",\"url\":\"https:\\\/\\\/volity.io\\\/de\\\/\",\"name\":\"Volity - Effortless, Affordable & Transparent Access To Financial Markets\",\"description\":\"Where Any Volume Finds Agility\",\"publisher\":{\"@id\":\"https:\\\/\\\/volity.io\\\/de\\\/#organization\"},\"alternateName\":\"Volity Empowers Financial Inclusion\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/volity.io\\\/de\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"de\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/volity.io\\\/de\\\/#organization\",\"name\":\"Volity\",\"alternateName\":[\"VLT\",\"Volity Group\"],\"url\":\"https:\\\/\\\/volity.io\\\/de\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/volity.io\\\/de\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/volity.io\\\/wp-content\\\/uploads\\\/2024\\\/08\\\/White-BG.webp\",\"contentUrl\":\"https:\\\/\\\/volity.io\\\/wp-content\\\/uploads\\\/2024\\\/08\\\/White-BG.webp\",\"width\":1920,\"height\":1357,\"caption\":\"VOLITY\"},\"image\":{\"@id\":\"https:\\\/\\\/volity.io\\\/de\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61570055360264\",\"https:\\\/\\\/x.com\\\/VolityBeat\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/volitygroup\",\"https:\\\/\\\/www.youtube.com\\\/@VolityYoutube\",\"https:\\\/\\\/www.tiktok.com\\\/@hellovolity\",\"https:\\\/\\\/t.me\\\/volitybeat\",\"https:\\\/\\\/www.trustpilot.com\\\/review\\\/volity.io\"],\"foundingDate\":\"2024\",\"legalName\":\"Volity Limited\",\"address\":{\"@type\":\"PostalAddress\",\"addressCountry\":\"CY\",\"addressLocality\":\"Limassol\",\"streetAddress\":\"67 Spyrou Kyprianou Avenue, Kyriakides Business Center, 2nd Floor\",\"postalCode\":\"4003\"},\"contactPoint\":[{\"@type\":\"ContactPoint\",\"contactType\":\"customer support\",\"email\":\"h<!--email_off-->ello@volity.io<!--/email_off-->\",\"availableLanguage\":[\"English\",\"German\",\"French\",\"Spanish\"],\"areaServed\":[\"EU\",\"GB\",\"Worldwide\"]}],\"knowsAbout\":[\"Forex trading\",\"Contract for difference (CFD) trading\",\"Cryptocurrency trading\",\"Gold and commodities trading\",\"Stock trading\",\"Indices trading\",\"Multi-asset investment platforms\",\"Risk management\"],\"subOrganization\":[{\"@type\":\"Organization\",\"name\":\"Volity Trade Ltd\",\"identifier\":\"Saint Lucia 2024-00059\",\"description\":\"Introducing broker for UBK Markets Ltd\"},{\"@type\":\"Organization\",\"name\":\"Volity Invest Ltd\",\"identifier\":\"Cyprus HE 452984\",\"description\":\"Payment agent\"},{\"@type\":\"Organization\",\"name\":\"Volity Limited\",\"identifier\":\"Hong Kong trademark 67964819\"}],\"description\":\"Providing easy-to-use, affordable and secure access to financial products with personalised experience, local market understanding, and unrivalled customer service.\",\"email\":\"h<!--email_off-->ello@volity.io<!--/email_off-->\",\"memberOf\":{\"@type\":\"Organization\",\"name\":\"CySEC, Cyprus Securities and Exchange Commission\",\"url\":\"https:\\\/\\\/www.cysec.gov.cy\\\/\",\"description\":\"Volity introduces clients to UBK Markets Ltd, a Cyprus Investment Firm authorised by CySEC under licence 186\\\/12.\"},\"hasCredential\":{\"@type\":\"EducationalOccupationalCredential\",\"name\":\"CySEC CIF licence (via UBK Markets Ltd)\",\"credentialCategory\":\"Regulatory authorisation\",\"recognizedBy\":{\"@type\":\"Organization\",\"name\":\"CySEC\",\"url\":\"https:\\\/\\\/www.cysec.gov.cy\\\/\"},\"identifier\":\"186\\\/12\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/volity.io\\\/alexander-bennett\\\/#person\",\"name\":\"Alexander Bennett\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/volity.io\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/A.Bennett-1.webp\",\"url\":\"https:\\\/\\\/volity.io\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/A.Bennett-1.webp\",\"contentUrl\":\"https:\\\/\\\/volity.io\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/A.Bennett-1.webp\",\"caption\":\"Alexander Bennett\"},\"description\":\"Alexander Bennett has spent over a decade reading markets, from institutional research desks to retail trading floors, and writes Volity's coverage of forex, crypto, commodities, and platforms. Certified in technical analysis through the International Federation of Technical Analysts and as a Financial Risk Manager, his work has been featured on DailyForex and TradingBeasts. His writing cuts through hype. The goal isn't moonshots; it's the disciplined edge that survives drawdowns. More on Alexander's background and approach: https:\\\/\\\/volity.io\\\/alexander-bennett\\\/\",\"sameAs\":[\"https:\\\/\\\/www.linkedin.com\\\/in\\\/alexanderbennettfm\\\/\",\"https:\\\/\\\/volity.io\\\/alexander-bennett\\\/\"],\"jobTitle\":\"Financial Analyst & Trading Strategy Expert\",\"givenName\":\"Alexander\",\"familyName\":\"Bennett\",\"url\":\"https:\\\/\\\/volity.io\\\/alexander-bennett\\\/\",\"worksFor\":{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/volity.io\\\/#organization\",\"name\":\"Volity\"},\"knowsAbout\":[\"Forex trading\",\"Cryptocurrency markets\",\"Technical analysis\",\"Risk management\",\"CFD trading\",\"Commodities trading\",\"Trading strategy\",\"MetaTrader 4\",\"MetaTrader 5\"],\"hasCredential\":[{\"@type\":\"EducationalOccupationalCredential\",\"name\":\"Technical Analysis Certification\",\"credentialCategory\":\"certification\",\"recognizedBy\":{\"@type\":\"Organization\",\"name\":\"International Federation of Technical Analysts\",\"url\":\"https:\\\/\\\/www.ifta.org\\\/\"}},{\"@type\":\"EducationalOccupationalCredential\",\"name\":\"Financial Risk Manager\",\"credentialCategory\":\"certification\",\"recognizedBy\":{\"@type\":\"Organization\",\"name\":\"Global Association of Risk Professionals\",\"url\":\"https:\\\/\\\/www.garp.org\\\/\"}}]},{\"@type\":\"FAQPage\",\"@id\":\"https:\\\/\\\/volity.io\\\/de\\\/cfd\\\/big-pharma-on-the-edge-patents-pitfalls-and-billions-at-stake\\\/#faq\",\"mainEntity\":[{\"@type\":\"Question\",\"name\":\"Cash-Rich... but Nowhere to Spend?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"For sector-specific stock investing context, see Marktsektoren: Rotations-Trends 2026, Blue-Chip-Aktien: Sind sie gut f\u00fcr Investitionen?, and Fundamentalanalyse: Bewertung des Aktienwerts. Pharma's pockets are deep - really deep. With over $700 billion in M&A capacity ready to go, you'd think the next wave of biotech deals would be booming. Except... there's a catch. The ideal acquisition targets - biotechs with real revenue and not just \\\"science experiments\\\" - are rare. And when deals do happen, they don't always pan out. Since 2018, around 80% of biotech IPOs have flopped, wiping out billions in investor capital and leaving M&A teams spooked.\"}},{\"@type\":\"Question\",\"name\":\"So, What Happens Next?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"To survive this shift, Big Pharma has to juggle three tough demands: Keep innovation alive - through internal R&D and external deals; Defend their patent arsenals - without triggering legal or political backlash; Deploy capital wisely - in a market that no longer rewards hype. Valuations may look cheap, but investors beware: some of these stocks are sitting on quicksand. The patent cliff isn't just a calendar event - it's a map of who's exposed, who's scrambling for new growth, and who's quietly building resilience.\"}},{\"@type\":\"Question\",\"name\":\"Can AI Be Trusted With Care Decisions?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"AI can streamline paperwork and flag errors. But when algorithms dictate care without real human oversight, it gets dangerous. Accountability is missing. Regulation lags. And patients are trapped in a system optimized less for health than for savings.\"}},{\"@type\":\"Question\",\"name\":\"What Happens When You Defund Discovery?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Cracks show quickly. Measles outbreaks are the worst in more than thirty years. Vaccine hesitancy is back on front pages. Biotech pipelines slow - not for lack of ideas, but for lack of grants to push them forward. Even the academic heavyweights aren't insulated. Harvard - yes, that Harvard - is under federal investigation over how federally funded research translates into patents. If regulators come down hard, the university-to-industry bridge could wobble, maybe break.\"}},{\"@type\":\"Question\",\"name\":\"Why Are We Doing This?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Politics, mostly. Science has no voting bloc, no quick wins. It's slow, technical, occasionally maddening - and expensive. When the budget knives come out, research is often first on the cutting board.\"}},{\"@type\":\"Question\",\"name\":\"How big is the 2026-2030 patent cliff actually, in dollar terms?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Industry consensus places branded-drug revenue exposed to loss-of-exclusivity at roughly $200 billion across the 2026-2030 window, with biologics representing a materially larger share than in prior cliff cycles. The FDA drug approvals and databases hub publishes the Orange Book and Purple Book reference lists that institutional desks reconcile against company-disclosed exclusivity calendars. The structural read for allocators: cliff exposure is highly concentrated in a handful of mega-franchises, and the dispersion across the major pharma names is wider than the headline aggregate suggests.\"}},{\"@type\":\"Question\",\"name\":\"How does the FDA approval cadence compare to historical norms in 2026?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The FDA Center for Drug Evaluation and Research approved a record cohort of novel drugs in 2024-2025, with cell and gene therapies and oncology leading the count. Investopedia coverage of pharma sector dynamics covers the sector framework with current market context, although its company list is dated. The 2026 read: regulatory throughput is supportive of new-launch momentum, but Medicare price negotiation has compressed the launch-economics distribution by a meaningful margin in U.S.-pricing-sensitive franchises.\"}},{\"@type\":\"Question\",\"name\":\"How should retail traders size pharma CFD exposure under EU rules?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Under the ESMA product intervention framework for retail CFDs, EU retail leverage on individual equities is capped at 5:1, with mandatory negative-balance protection and standardised risk warnings. Pharma names carry asymmetric event risk (FDA decisions, trial data drops, Medicare negotiation announcements) that materially widens stop-loss requirements relative to broad-index exposure. Volity, accessed via UBK Markets under CySEC licence 186\\\/12, lists liquid pharma single-stock CFDs with segregated client funds and standardised retail disclosure.\"}}],\"speakable\":{\"@type\":\"SpeakableSpecification\",\"cssSelector\":[\"h1\",\".entry-content > p:first-of-type\",\".entry-content h2\",\".faq-question\",\"[data-volity-takeaways]\"]}}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Big Pharma am Abgrund - Volity","description":"Wie KI-Ablehnungen, auslaufende Patente, schrumpfender Versicherungsschutz und politische Angriffe das US-Gesundheitswesen umformen.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/volity.io\/de\/cfd\/big-pharma-on-the-edge-patents-pitfalls-and-billions-at-stake\/","og_locale":"de_DE","og_type":"article","og_title":"Big Pharma am Abgrund: Patente, Fallen und Milliarden auf dem Spiel","og_description":"Wie KI-Ablehnungen, auslaufende Patente, schrumpfender Versicherungsschutz und politische Angriffe das US-Gesundheitswesen umformen.","og_url":"https:\/\/volity.io\/de\/cfd\/big-pharma-on-the-edge-patents-pitfalls-and-billions-at-stake\/","og_site_name":"Volity","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61570055360264","article_published_time":"2025-08-18T07:18:45+00:00","article_modified_time":"2026-05-19T18:51:12+00:00","og_image":[{"width":1456,"height":816,"url":"https:\/\/volity.io\/wp-content\/uploads\/2025\/08\/Rod-of-Asclepius.webp","type":"image\/webp"}],"author":"Alexander Bennett","twitter_card":"summary_large_image","twitter_creator":"@VolityBeat","twitter_site":"@VolityBeat","twitter_misc":{"Written by":"Alexander Bennett","Est. reading time":"13\u00a0Minuten"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/volity.io\/de\/cfd\/big-pharma-on-the-edge-patents-pitfalls-and-billions-at-stake\/#article","isPartOf":{"@id":"https:\/\/volity.io\/de\/cfd\/big-pharma-on-the-edge-patents-pitfalls-and-billions-at-stake\/"},"author":{"name":"Alexander Bennett","@id":"https:\/\/volity.io\/de\/#\/schema\/person\/b331ae22e808d4e5c67047ab75976841"},"headline":"Big Pharma am Abgrund: Patente, Fallen und Milliarden auf dem Spiel","datePublished":"2025-08-18T07:18:45+00:00","dateModified":"2026-05-19T18:51:12+00:00","mainEntityOfPage":{"@id":"https:\/\/volity.io\/de\/cfd\/big-pharma-on-the-edge-patents-pitfalls-and-billions-at-stake\/"},"wordCount":2606,"publisher":{"@id":"https:\/\/volity.io\/de\/#organization"},"image":{"@id":"https:\/\/volity.io\/de\/cfd\/big-pharma-on-the-edge-patents-pitfalls-and-billions-at-stake\/#primaryimage"},"thumbnailUrl":"https:\/\/volity.io\/wp-content\/uploads\/2025\/08\/Rod-of-Asclepius.webp","articleSection":["CFD"],"inLanguage":"de","speakable":{"@type":"SpeakableSpecification","cssSelector":["h1",".entry-content > p:first-of-type",".entry-content h2",".faq-question","[data-volity-takeaways]"]}},{"@type":"WebPage","@id":"https:\/\/volity.io\/de\/cfd\/big-pharma-on-the-edge-patents-pitfalls-and-billions-at-stake\/","url":"https:\/\/volity.io\/de\/cfd\/big-pharma-on-the-edge-patents-pitfalls-and-billions-at-stake\/","name":"Big Pharma am Abgrund - Volity","isPartOf":{"@id":"https:\/\/volity.io\/de\/#website"},"primaryImageOfPage":{"@id":"https:\/\/volity.io\/de\/cfd\/big-pharma-on-the-edge-patents-pitfalls-and-billions-at-stake\/#primaryimage"},"image":{"@id":"https:\/\/volity.io\/de\/cfd\/big-pharma-on-the-edge-patents-pitfalls-and-billions-at-stake\/#primaryimage"},"thumbnailUrl":"https:\/\/volity.io\/wp-content\/uploads\/2025\/08\/Rod-of-Asclepius.webp","datePublished":"2025-08-18T07:18:45+00:00","dateModified":"2026-05-19T18:51:12+00:00","description":"Wie KI-Ablehnungen, auslaufende Patente, schrumpfender Versicherungsschutz und politische Angriffe das US-Gesundheitswesen umformen.","breadcrumb":{"@id":"https:\/\/volity.io\/de\/cfd\/big-pharma-on-the-edge-patents-pitfalls-and-billions-at-stake\/#breadcrumb"},"inLanguage":"de","potentialAction":[{"@type":"ReadAction","target":["https:\/\/volity.io\/de\/cfd\/big-pharma-on-the-edge-patents-pitfalls-and-billions-at-stake\/"]}],"speakable":{"@type":"SpeakableSpecification","cssSelector":["h1",".entry-content > p:first-of-type",".entry-content h2",".faq-question","[data-volity-takeaways]"]}},{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/volity.io\/de\/cfd\/big-pharma-on-the-edge-patents-pitfalls-and-billions-at-stake\/#primaryimage","url":"https:\/\/volity.io\/wp-content\/uploads\/2025\/08\/Rod-of-Asclepius.webp","contentUrl":"https:\/\/volity.io\/wp-content\/uploads\/2025\/08\/Rod-of-Asclepius.webp","width":1456,"height":816,"caption":"Rod of Asclepius"},{"@type":"BreadcrumbList","@id":"https:\/\/volity.io\/de\/cfd\/big-pharma-on-the-edge-patents-pitfalls-and-billions-at-stake\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/volity.io\/de\/"},{"@type":"ListItem","position":2,"name":"Big Pharma am Abgrund: Patente, Fallen und Milliarden auf dem Spiel"}]},{"@type":"WebSite","@id":"https:\/\/volity.io\/de\/#website","url":"https:\/\/volity.io\/de\/","name":"Volity - Effortless, Affordable & Transparent Access To Financial Markets","description":"Where Any Volume Finds Agility","publisher":{"@id":"https:\/\/volity.io\/de\/#organization"},"alternateName":"Volity Empowers Financial Inclusion","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/volity.io\/de\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"de"},{"@type":"Organization","@id":"https:\/\/volity.io\/de\/#organization","name":"Volity","alternateName":["VLT","Volity Group"],"url":"https:\/\/volity.io\/de\/","logo":{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/volity.io\/de\/#\/schema\/logo\/image\/","url":"https:\/\/volity.io\/wp-content\/uploads\/2024\/08\/White-BG.webp","contentUrl":"https:\/\/volity.io\/wp-content\/uploads\/2024\/08\/White-BG.webp","width":1920,"height":1357,"caption":"VOLITY"},"image":{"@id":"https:\/\/volity.io\/de\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61570055360264","https:\/\/x.com\/VolityBeat","https:\/\/www.linkedin.com\/company\/volitygroup","https:\/\/www.youtube.com\/@VolityYoutube","https:\/\/www.tiktok.com\/@hellovolity","https:\/\/t.me\/volitybeat","https:\/\/www.trustpilot.com\/review\/volity.io"],"foundingDate":"2024","legalName":"Volity Limited","address":{"@type":"PostalAddress","addressCountry":"CY","addressLocality":"Limassol","streetAddress":"67 Spyrou Kyprianou Avenue, Kyriakides Business Center, 2nd Floor","postalCode":"4003"},"contactPoint":[{"@type":"ContactPoint","contactType":"customer support","email":"h<!--email_off-->ello@volity.io<!--/email_off-->","availableLanguage":["English","German","French","Spanish"],"areaServed":["EU","GB","Worldwide"]}],"knowsAbout":["Forex trading","Contract for difference (CFD) trading","Cryptocurrency trading","Gold and commodities trading","Stock trading","Indices trading","Multi-asset investment platforms","Risk management"],"subOrganization":[{"@type":"Organization","name":"Volity Trade Ltd","identifier":"Saint Lucia 2024-00059","description":"Introducing broker for UBK Markets Ltd"},{"@type":"Organization","name":"Volity Invest Ltd","identifier":"Cyprus HE 452984","description":"Payment agent"},{"@type":"Organization","name":"Volity Limited","identifier":"Hong Kong trademark 67964819"}],"description":"Providing easy-to-use, affordable and secure access to financial products with personalised experience, local market understanding, and unrivalled customer service.","email":"h<!--email_off-->ello@volity.io<!--/email_off-->","memberOf":{"@type":"Organization","name":"CySEC, Cyprus Securities and Exchange Commission","url":"https:\/\/www.cysec.gov.cy\/","description":"Volity introduces clients to UBK Markets Ltd, a Cyprus Investment Firm authorised by CySEC under licence 186\/12."},"hasCredential":{"@type":"EducationalOccupationalCredential","name":"CySEC CIF licence (via UBK Markets Ltd)","credentialCategory":"Regulatory authorisation","recognizedBy":{"@type":"Organization","name":"CySEC","url":"https:\/\/www.cysec.gov.cy\/"},"identifier":"186\/12"}},{"@type":"Person","@id":"https:\/\/volity.io\/alexander-bennett\/#person","name":"Alexander Bennett","image":{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/volity.io\/wp-content\/uploads\/2026\/03\/A.Bennett-1.webp","url":"https:\/\/volity.io\/wp-content\/uploads\/2026\/03\/A.Bennett-1.webp","contentUrl":"https:\/\/volity.io\/wp-content\/uploads\/2026\/03\/A.Bennett-1.webp","caption":"Alexander Bennett"},"description":"Alexander Bennett has spent over a decade reading markets, from institutional research desks to retail trading floors, and writes Volity's coverage of forex, crypto, commodities, and platforms. Certified in technical analysis through the International Federation of Technical Analysts and as a Financial Risk Manager, his work has been featured on DailyForex and TradingBeasts. His writing cuts through hype. The goal isn't moonshots; it's the disciplined edge that survives drawdowns. More on Alexander's background and approach: https:\/\/volity.io\/alexander-bennett\/","sameAs":["https:\/\/www.linkedin.com\/in\/alexanderbennettfm\/","https:\/\/volity.io\/alexander-bennett\/"],"jobTitle":"Financial Analyst & Trading Strategy Expert","givenName":"Alexander","familyName":"Bennett","url":"https:\/\/volity.io\/alexander-bennett\/","worksFor":{"@type":"Organization","@id":"https:\/\/volity.io\/#organization","name":"Volity"},"knowsAbout":["Forex trading","Cryptocurrency markets","Technical analysis","Risk management","CFD trading","Commodities trading","Trading strategy","MetaTrader 4","MetaTrader 5"],"hasCredential":[{"@type":"EducationalOccupationalCredential","name":"Technical Analysis Certification","credentialCategory":"certification","recognizedBy":{"@type":"Organization","name":"International Federation of Technical Analysts","url":"https:\/\/www.ifta.org\/"}},{"@type":"EducationalOccupationalCredential","name":"Financial Risk Manager","credentialCategory":"certification","recognizedBy":{"@type":"Organization","name":"Global Association of Risk Professionals","url":"https:\/\/www.garp.org\/"}}]},{"@type":"FAQPage","@id":"https:\/\/volity.io\/de\/cfd\/big-pharma-on-the-edge-patents-pitfalls-and-billions-at-stake\/#faq","mainEntity":[{"@type":"Question","name":"Cash-Rich... but Nowhere to Spend?","acceptedAnswer":{"@type":"Answer","text":"For sector-specific stock investing context, see Marktsektoren: Rotations-Trends 2026, Blue-Chip-Aktien: Sind sie gut f\u00fcr Investitionen?, and Fundamentalanalyse: Bewertung des Aktienwerts. Pharma's pockets are deep - really deep. With over $700 billion in M&A capacity ready to go, you'd think the next wave of biotech deals would be booming. Except... there's a catch. The ideal acquisition targets - biotechs with real revenue and not just \"science experiments\" - are rare. And when deals do happen, they don't always pan out. Since 2018, around 80% of biotech IPOs have flopped, wiping out billions in investor capital and leaving M&A teams spooked."}},{"@type":"Question","name":"So, What Happens Next?","acceptedAnswer":{"@type":"Answer","text":"To survive this shift, Big Pharma has to juggle three tough demands: Keep innovation alive - through internal R&D and external deals; Defend their patent arsenals - without triggering legal or political backlash; Deploy capital wisely - in a market that no longer rewards hype. Valuations may look cheap, but investors beware: some of these stocks are sitting on quicksand. The patent cliff isn't just a calendar event - it's a map of who's exposed, who's scrambling for new growth, and who's quietly building resilience."}},{"@type":"Question","name":"Can AI Be Trusted With Care Decisions?","acceptedAnswer":{"@type":"Answer","text":"AI can streamline paperwork and flag errors. But when algorithms dictate care without real human oversight, it gets dangerous. Accountability is missing. Regulation lags. And patients are trapped in a system optimized less for health than for savings."}},{"@type":"Question","name":"What Happens When You Defund Discovery?","acceptedAnswer":{"@type":"Answer","text":"Cracks show quickly. Measles outbreaks are the worst in more than thirty years. Vaccine hesitancy is back on front pages. Biotech pipelines slow - not for lack of ideas, but for lack of grants to push them forward. Even the academic heavyweights aren't insulated. Harvard - yes, that Harvard - is under federal investigation over how federally funded research translates into patents. If regulators come down hard, the university-to-industry bridge could wobble, maybe break."}},{"@type":"Question","name":"Why Are We Doing This?","acceptedAnswer":{"@type":"Answer","text":"Politics, mostly. Science has no voting bloc, no quick wins. It's slow, technical, occasionally maddening - and expensive. When the budget knives come out, research is often first on the cutting board."}},{"@type":"Question","name":"How big is the 2026-2030 patent cliff actually, in dollar terms?","acceptedAnswer":{"@type":"Answer","text":"Industry consensus places branded-drug revenue exposed to loss-of-exclusivity at roughly $200 billion across the 2026-2030 window, with biologics representing a materially larger share than in prior cliff cycles. The FDA drug approvals and databases hub publishes the Orange Book and Purple Book reference lists that institutional desks reconcile against company-disclosed exclusivity calendars. The structural read for allocators: cliff exposure is highly concentrated in a handful of mega-franchises, and the dispersion across the major pharma names is wider than the headline aggregate suggests."}},{"@type":"Question","name":"How does the FDA approval cadence compare to historical norms in 2026?","acceptedAnswer":{"@type":"Answer","text":"The FDA Center for Drug Evaluation and Research approved a record cohort of novel drugs in 2024-2025, with cell and gene therapies and oncology leading the count. Investopedia coverage of pharma sector dynamics covers the sector framework with current market context, although its company list is dated. The 2026 read: regulatory throughput is supportive of new-launch momentum, but Medicare price negotiation has compressed the launch-economics distribution by a meaningful margin in U.S.-pricing-sensitive franchises."}},{"@type":"Question","name":"How should retail traders size pharma CFD exposure under EU rules?","acceptedAnswer":{"@type":"Answer","text":"Under the ESMA product intervention framework for retail CFDs, EU retail leverage on individual equities is capped at 5:1, with mandatory negative-balance protection and standardised risk warnings. Pharma names carry asymmetric event risk (FDA decisions, trial data drops, Medicare negotiation announcements) that materially widens stop-loss requirements relative to broad-index exposure. Volity, accessed via UBK Markets under CySEC licence 186\/12, lists liquid pharma single-stock CFDs with segregated client funds and standardised retail disclosure."}}],"speakable":{"@type":"SpeakableSpecification","cssSelector":["h1",".entry-content > p:first-of-type",".entry-content h2",".faq-question","[data-volity-takeaways]"]}}]}},"yoast_meta":{"yoast_wpseo_title":"Big Pharma am Abgrund - Volity","yoast_wpseo_metadesc":"Wie KI-Ablehnungen, auslaufende Patente, schrumpfender Versicherungsschutz und politische Angriffe das US-Gesundheitswesen umformen.","yoast_wpseo_focuskw":"Pharma","yoast_wpseo_opengraph-title":"","yoast_wpseo_opengraph-description":"","yoast_wpseo_twitter-title":"","yoast_wpseo_twitter-description":""},"yoast_title":"Big Pharma am Abgrund - Volity","yoast_metadesc":"Wie KI-Ablehnungen, auslaufende Patente, schrumpfender Versicherungsschutz und politische Angriffe das US-Gesundheitswesen umformen.","_links":{"self":[{"href":"https:\/\/volity.io\/de\/wp-json\/wp\/v2\/posts\/33404","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/volity.io\/de\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/volity.io\/de\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/volity.io\/de\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/volity.io\/de\/wp-json\/wp\/v2\/comments?post=33404"}],"version-history":[{"count":5,"href":"https:\/\/volity.io\/de\/wp-json\/wp\/v2\/posts\/33404\/revisions"}],"predecessor-version":[{"id":35368,"href":"https:\/\/volity.io\/de\/wp-json\/wp\/v2\/posts\/33404\/revisions\/35368"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/volity.io\/de\/wp-json\/wp\/v2\/media\/17935"}],"wp:attachment":[{"href":"https:\/\/volity.io\/de\/wp-json\/wp\/v2\/media?parent=33404"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/volity.io\/de\/wp-json\/wp\/v2\/categories?post=33404"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/volity.io\/de\/wp-json\/wp\/v2\/tags?post=33404"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}